What could be bigger than a little blue pill that turned a common problem for the bedroom-challenged man into a marketing marvel, creating a $2.5 billion-a-year pharmaceutical niche that once featured a president wannabe as its prime-time pitchman?Chris Early hopes it’s a mint-flavored tablet for what may be an even more common problem than impotence. He’s the CEO for Enhance Biotech, a company developing what could become the first pill specifically developed to treat rapid ejaculation -- the new name for premature ejaculation, one of the most common sexual disorders in men. Early’s drug, currently known as LI 301, is still in development, and wouldn’t hit the market until 2007, assuming it receives FDA approval. A recently completed preliminary trial involving 30 couples produced promising results, Early says. These study results have not been published.
